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Interferon lambdas (IFNl) (also known as type III IFNs) are critical cytokines that combat
infection predominantly at barrier tissues, such as the lung, liver, and gastrointestinal tract.
Humans have four IFNls (1–4), where IFNl1–3 show ~80%–95% homology, and IFNl4 is
the most divergent displaying only ~30% sequence identity. Variants in IFNl4 in humans
are associated with the outcome of infection, such as with hepatitis C virus. However, how
IFNl4 variants impact cytokine signalling in other tissues and how well this is conserved is
largely unknown. In this study, we address whether differences in antiviral signalling exist
between IFNl4 variants in human hepatocyte and intestinal cells, comparing them to
IFNl3. We demonstrate that compared to IFNl3, wild-type human IFNl4 induces a
signalling response with distinct magnitudes and kinetics, which is modified by naturally
occurring variants P70S and K154E in both cell types. IFNl4’s distinct antiviral response
was more rapid yet transient compared to IFNl1 and 3. Additionally, divergent antiviral
kinetics were also observed using non-human primate IFNls and cell lines. Furthermore,
an IFNl4-like receptor-interacting interface failed to alter IFNl1’s kinetics. Together, our
data provide further evidence that major functional differences exist within the IFNl gene
family. These results highlight the possible tissue specialisation of IFNls and encourage
further investigation of the divergent, non-redundant activities of IFNl4 and other IFNls.
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Viral infections of mucosal surfaces like the lung, gut, and liver
[such as influenza, rotavirus and hepatitis C virus (HCV)]
remain major drivers of global morbidity and mortality in
the human population (1). The host innate immune response
is a critical determinant of the outcome of infection and as
such, its stimulation can influence clinical outcomes (2).
Following sensing of viral infection, several antiviral and
immunoregulatory factors like cytokines are induced that act
to limit viral replication and promote clearance and long-term
immunity (3). Interferons (IFNs) are one important group of
such cytokines with potent antiviral activity (4). There exist three
recognised families of IFNs: the type I IFNs (alpha 1-13, beta,
epsilon, kappa, and omega in humans), type II IFNs (gamma),
and type III IFNs [lambdas (l) 1–4] (5). Types I and III IFNs are
rapidly induced and secreted following sensing of infection in
most nucleated cells. These secreted IFNs then act in turn on the
infected cell and on neighbouring uninfected cells to induce the
production of hundreds of interferon stimulated genes (ISGs) via
activation of the Janus kinase–signal transducer and activator of
transcription (JAK-STAT) pathway. Although they share similar
downstream signalling pathways and lead to the activation of
similar ISGs, type I and III IFNs utilise distinct cell surface
receptor complexes (6). Type I IFNs use the ubiquitously
expressed IFNAR1 and IFNAR2 heterodimeric complex, whilst
type III IFNs use the IFNlR1 and IL10R2 heterodimeric
complex. Although also found on some immune cell types (7),
IFNlR1 is predominantly expressed on epithelial cells at the so-
called barrier tissues (8), including the respiratory and
gastrointestinal tracts, and hepatocytes in the liver of humans
(9), which provides type III IFNs distinct traits specialised in the
protection of mucosal surfaces compared to type I IFNs (10–12).
Although they share a receptor complex, there is emerging
evidence that not all type III IFNs have redundant features (13).
The human IFNls, namely, IFNl1, IFNl2, and IFNl3, all share
>80% homology, yet compared to IFNl4, they exhibit only ~30%
homology (6, 9, 13). Whilst all type III IFNs are more recently
discovered in comparison to type I IFNs (4, 6, 9), IFNl4 was the
latest addition to the family being only identified in 2013 (13).
The outcome of HCV infection is associated with genetic
variation in the human IFNL locus [e.g., “IL28B” single
nucleotide polymorphisms (SNPs)], likely mediated by variants
within IFNL4 (14). IFNl4, like other IFNls, has potent antiviral
activity (15). These same genetic variants are also associated with
extra-hepatic infections, such as enteroviral infection in the
respiratory tract (16). There are two common loss-of-function
SNPs in human IFNL4, encoding a frameshift (rs12979860), and
a non-synonymous variant P70S (rs117648444, which encodes a
proline to serine mutation at position 70), respectively (13, 14).
Whilst the frameshift ablates IFNl4 production, P70S reduces
the potency of ISG induction by IFNl4 (14, 17, 18). Interestingly,
it is these hypo- or inactive alleles that are associated with
protection from chronic HCV infection in humans (13, 14).
Further investigation into the functional diversity of IFNl4
identified two rare variants that affect IFNl4 activity, including
an additional hypoactive variant L79F (leucine to phenylalanineFrontiers in Immunology | www.frontiersin.org 2at position 79) and K154E (lysine to glutamic acid at position
154), which dramatically enhances IFNl4 antiviral activity by
increasing its secretion and potency (17). Intriguingly, although
K154 is nearly ubiquitous in the human population, E154 is the
ancestral amino acid at this position in non-human primates and
other mammals. E154 was found in a small number of extant
humans. Accordingly, chimpanzee and rhesus macaque IFNl4
have enhanced antiviral activity relative to wild-type human
IFNl4, which can be reversed by an E154K mutation. Together,
the evolutionary data suggest a step-wise attenuation of IFNl4
activity (E154K > P70S > TT frameshift) unique to modern
humans (13), which is consistent with the non-redundancy of
IFNl4 compared to other IFNls. However, which precise unique
biological feature(s) of IFNl4 that are non-redundant (and thus
have been acted upon by evolution) are poorly understood and
only beginning to be unravelled (14, 19, 20).
Following on from our previous work (11, 17), we wished to
determine how the antiviral activity of IFNl4 and its variants
and homologues changed in a time-dependent manner,
compared to other IFNls. To test this hypothesis, we
characterised the kinetics of signalling and antiviral activity of
a panel of IFNl4 variants in human hepatocyte and human
intestinal epithelial cells compared to IFNl3. Together, our work
demonstrates the unique kinetics of IFNl4 activity compared to
other IFNls, which is conserved within and between species.
Further work on the intrinsic differences between IFNl4 and
other IFNs is warranted.RESULTS
IFNl Variants Display Unique STAT1
Phosphorylation Kinetics
Binding of IFNls to their receptor complex leads to activation of
downstream signalling cascades that ultimately lead to the
establishment of an antiviral state (6). The JAK/STAT pathway
is one of the most critical and well-characterised pathways
activated following IFNl binding. An emerging view is that the
kinetics of such a downstream response is a crucial determinant
of the antiviral potential of IFNls (11, 20). To probe the
temporal basis of IFNl signalling in greater detail, we first
measured phosphorylation of STAT1 over time at Y701
(Figure 1). Human hepatocyte HepaRG monolayers were
incubated with conditioned media estimated to contain
equivalent amounts of IFNls (IFNl3, IFNl4 WT, P70S, L79F,
and K154E) for 15, 30, 60, 120, and 360 min, and 24 h. Following
stimulation, protein lysates were harvested, and STAT1
phosphorylation was assayed by immunoblot analysis
(Figure 1A). Conditioned media generated following
transfection of an enhanced green fluorescent protein (EGFP)-
expressing plasmid served as a negative control. Results showed
that IFNl3 and a number of IFNl4 variants induced detectable
levels of pSTAT1 (Figure 1A, quantified in Supplementary
Figure 1A). L79F gave extremely low levels of pSTAT1 (data
not shown), which likely correlates with its very limited activity
as described previously (17). Interestingly, IFNl3 and IFNl4November 2021 | Volume 12 | Article 772588
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(Figure 1A and Supplementary Figure 1A). Whilst all IFNls
peaked around similar times (30 min to 1 h), IFNl4 WT and
P70S showed clear transient activation, whilst IFNl3 and K154E
displayed persistent activation of pSTAT1. Importantly, levels of
pSTAT1 correlated with previously measured antiviral potential
for three IFNl4 variants K154E >WT > P70S (17). As IFNls can
also signal in other tissues apart from the human liver (8, 21),
and there is an emerging role for IFNl4 in extra-hepatic
environments, we assayed whether human colon carcinoma
cells (T84) were capable of inducing pSTAT1 in response to
IFNl4 and its variants. Intestinal T84 cells were treated and
incubated with conditioned media containing equivalentFrontiers in Immunology | www.frontiersin.org 3amounts of IFNls (IFNl3, IFNl4 WT, P70S, and K154E), and
their induction of pSTAT1 was assayed over time by
immunoblot analysis (Figure 1B and Supplementary
Figure 1B). We observed similar trends as to HepaRG,
although differences in amplitude of pSTAT1 induction were
noted, especially for IFNl4 K154E in T84 cells. Together, these
results show that both hepatic and intestinal cell lines can
respond to both IFNl3 and IFNl4 and display variant-specific
inductions of the JAK/STAT pathway.
IFNl Variants Display Different Levels of
ISG Induction
Phosphorylation of STAT1 following receptor complex
engagement by IFNls results in STAT1/2 dimer formation and
translocation to the nucleus to induce ISG transcription, which
ultimately leads to the production of antiviral proteins and the
establishment of an antiviral state (6). Our previous work
showed that IFNl variants induced different levels of ISG
expression when measured at 24 h (17). To ascertain whether
this ISG expression varied at earlier times after incubation in
concert with the kinetics of pSTAT1 activation, we measured the
relative induction of a panel of core ISGs (IFIT1, MX1, ISG15,
and RSAD2/VIPERIN) compared to EGFP-treated conditioned
media in HepaRG cells (Figures 2A–D) and T84 cells
(Figures 2E–H). Compared to EGFP-conditioned media
stimulated cells, all IFNls induced measurable increases in ISG
mRNA in HepaRG cells but with discernible differences in
magnitude. T84 cells also showed ISG induction for four of the
supernatants tested (Figures 2E–H). Additionally, looking at
relative fold change, T84 cells gave a lower induction of all ISGs
as compared to HepaRG cells (Figure 2). The magnitudes of ISG
induction for both cell lines mirrored the pSTAT1 induction that
was observed in Figure 1 (IFNl3/K154E > WT > P70S > L79F).
IFNl4 K154E induced a similar pattern of ISG induction as
IFNl3 in both cell lines. Interestingly the kinetics of ISG
induction was distinct to each cell line. In HepaRG cells, all
IFNls induced an early peak induction of ISGs, which
subsequently declined over time. Moreover, IFNl4 K154E
demonstrated a slightly faster induction and peaked by 2 h
whilst all other IFNls tested peaked at 6 h. By contrast, IFNl3
and the IFNl4 K154E showed no or little decline in ISG
induction after induction at either 2 or 6 h in T84 cells
(Figures 2E–H). Additionally, T84 cells yielded low to almost
undetectable induction of ISGs following IFNl4 WT and P70S
treatment. Together, these results show that K154E provides
similar stimulatory activity to IFNl3 and that this is far greater
than for either IFNl4 WT or P70S, which are the most common
IFNl4 variants in the human population.
IFNl Variants Have Distinct Antiviral
Activity in Intestinal Cells
Induction of an antiviral state is the major downstream
consequence of IFN signalling. To determine how STAT1
phosphorylation and ISG expression correlate with antiviral
activity, we infected the hepatic and intestinal cell models with
two different viruses, EMCV and VSV. Both EMCV and VSV areA
B
FIGURE 1 | IFNls each have a distinct kinetic of STAT1 phosphorylation.
HepaRG (A) and T84 (B) cells were incubated with IFNls (IFNl3-HiBiT,
IFNl4-HiBiT): WT, P70S, and K154E for the indicated times and the levels of
pSTAT1 were assayed by immunoblot. Beta-tubulin (HepaRG) or beta-actin
(T84) served as loading controls. EGFP (A) or timepoint 0 (B) serves as a
conditioned media control. Representative images of two or three replicates
are shown from at least two independent protein batches.November 2021 | Volume 12 | Article 772588








FIGURE 2 | IFNl variants induce unique magnitudes of ISG mRNA. HepaRG (A–D) and T84 (E–H) cells were incubated with IFNls [IFNl3-HiBiT (red); IFNl4-HiBiT:
WT (blue), P70S (purple), L79F (yellow), and K154E (cyan)] for indicated times. At the respective time, total RNA was isolated, and qRT-PCR was performed for
ISGs: IFIT1 (A, E), ISG15 (B, F), MX1 (C, G), and RSAD2/VIPERIN (D, H). Mock control cells were treated with conditioned media from EGFP-plasmid transfected
HEK-293T cells, and all values were normalised against this value at each time. GAPDH (HepaRG) or HPRT1 (T84 cells) were used as housekeeping genes. L79F did
not induce any detectable ISG induction in T84 cells. Error bars represent the mean ± SEM from two to three biological replicates from at least two independent
protein batches.Frontiers in Immunology | www.frontiersin.org November 2021 | Volume 12 | Article 7725884
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which makes them suitable for assessing the kinetics of antiviral
activity. EMCV infectivity and replication were assayed by
determining the cytopathic effects of the virus, whilst a VSV
encoding luciferase (VSV-luc) was deployed and its infectivity
was measured by luciferase assay. HepaRG and T84 cells were
treated with increasing concentrations of EGFP or IFNl3 or
IFNl4-containing supernatants at 24 h prior to virus infection.
Following IFNl pretreatment, cells were infected with EMCV or
VSV [multiplicity of infection (MOI) of 0.3 and 1, respectively]
in the continuous presence of IFNls, and infection was assayed
at 24 h post-infection for EMCV (Figure 3A) and 8 h post-
infection for VSV (Figures 3B, C). Different assay times for VSV
versus EMCV were due to differences in replication kinetics and
cytopathic effects of either virus. Consistent with our previous
work (17, 21), results show that VSV infection was inhibited by
all IFNs in both cell lines (Figures 3B, C). IFNl3 was the most
potent IFN, as it reduced VSV infection with 10% of the
maximum concentration in both HepRG and T84 cells. IFNl4
WT and K154E showed similar antiviral activity; however, a
much higher concentration of these two IFNs was required to
reach a similar potency as IFNl3. Consistent with previous low
pSTAT1 and ISG inductions, P70S was only able to slightly
reduce virus infection even at the highest concentrations in both
cell lines. T84 cells were poorly infected with EMCV and highly
resistant to the cytopathic effects of the virus, and therefore,
antiviral activity was not assayed in this cell line, but similar
patterns of antiviral activity were seen for HepaRG cells infected
with EMCV (Figure 3A).
IFNl Variants Have Distinct Kinetics of
Antiviral Activity
Having established antiviral assays in both liver- and intestinal-
derived cell lines, we wished to determine whether IFNl activity
was time dependent and whether the continuous presence of
IFNls was required to maintain their antiviral activity.
Therefore, we performed infections and antiviral assays over
time, both in the continuous presence of IFNls but also in cells
that had been pretreated with IFNls for varying lengths of time,
yet the cytokines were then removed, monolayers washed, and
fresh media provided (“non-washed” and “washed”, respectively,
Figure 4A) prior to infection. Initially, we conducted
experiments in T84 cells that were infected with VSV following
IFNl pretreatment (Figures 4B–E). For clarity, it should be
noted that the following data are presented differently than those
in Figure 3. In agreement with the data presented in Figure 3, all
IFNls demonstrated antiviral activity with IFNl3 and IFNl4
P70S showing the greatest and least potency, respectively. The
peak of IFNl3 activity was delayed relative to all IFNl4s.
Moreover, we found that shorter incubation times with IFNl3
followed by its removal before infection reduced its antiviral
activity to a greater extent compared to the three IFNl4 variants
used in the experiment (compare early time points in Figure 4B
with Figures 4C–E); comparison of activity between washed and
unwashed was significant (t-test) at all time points for IFNl3,
whilst for IFNl4s, it was only significant for the first or secondFrontiers in Immunology | www.frontiersin.org 5time points. In HepaRG cells infected with EMCV, we observed a
similar pattern, i.e., removal of IFNl3 after relatively short
incubation (2 h) with cells gave a greater reduction in antiviral
activity compared to the same timepoint for the IFNl4 variants
(Figures 4F–I); when compared with the difference between
washed and unwashed for IFNl4, that of IFNl3 reached
statistical significance (t-test). In addition, we observed that all
IFNls generally gave less antiviral activity after removal at the
time of infection compared to activities in the continuous
presence of the proteins. From these experiments, we suggest
that IFNl4 proteins may be more tightly bound to the
heteromeric cell receptor as compared to IFNl3. Alternatively,
signalling with IFNl4 is maintained for a longer period as
compared to IFNl3. To further assess the contribution of IFN-
cell contact time compared to signalling time, we repeated the
wash experiments in HepaRG cells with EMCV, but, on this
occasion, cells were incubated with the IFNls at 24 h prior to
infection but then removed by washing at differing times before
virus addition (Supplementary Figure S2). The results show a
greater decline in antiviral activity (~15-fold) from 24 h
incubation to 6 and 2 h incubation for IFNl3 compared to
IFNl4 WT and IFNl4 K154E, which showed reductions in
activity by ~0.75-4 fold.
Divergent Kinetics Is Independent of
Human IFNl System
Our data suggest that in human cells, human IFNl4 and its
variants induce a distinct antiviral response compared with
human IFNl3. As previous work has demonstrated that IFNl4
from different primate species have varying levels of antiviral
activity (17, 22), we next explored whether the distinct signalling
kinetics that we observed were also species specific. We first
analysed the amino acid homology between IFNl3, IFNl4,
IFNlR1, and IL10R2 in humans, chimpanzees, and rhesus
macaques (Figure 5A). Results showed that although the
various orthologues shared a high degree of homology (92-
97%), there were differences that could affect activity given that
even a single amino acid change can alter signalling as in IFNl4
variants P70S and K154E. Given these genetic differences, we
next tested the antiviral kinetics of non-human IFNls. First, we
treated human HepaRG cells with human and non-human
IFNls as described in Supplementary Figure 2, by treating
cells for 2, 6, and 24 h, and then removing the cytokines prior
to infection with EMCV at 24 h after initial stimulation
(Figure 5B). For these experiments, we utilised non-human
primate IFNl3 or IFNl4 proteins containing a C-terminal
FLAG tag, which we characterised previously (17). In these
experiments, we utilised IFNl4 K154E as a model human
IFNl4, since it gave robust levels of detectable antiviral
activity, with kinetics broadly similar to IFNl4 WT. All IFNls
had antiviral activity against EMCV with chimpanzee IFNl4
having greater activity than human and macaque IFNl4
(Figure 5C), whilst human IFNl3 had greater activity than
macaque IFNl3 (Figure 5D). Similar to human variants, the
peak of IFNl3 activity was delayed relative to all IFNl4s. IFNl3
washing experiments demonstrated that like human IFNl4,November 2021 | Volume 12 | Article 772588
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removal than human or macaque IFNl3 (Figures 5C, D). To
determine if these characteristics also occurred in non-human
cells, we repeated these experiments in the rhesus macaque
respiratory epithelial cell line LLCMK2 (Figures 5E, F). Results
showed that all IFNl4s had similar kinetics of antiviral activity
but different levels of potencies as found in HepaRG cells.
Washing following immediate infection supported the initial
washing experiments with IFNl3 antiviral activity being more
sensitive to early removal of cytokine (Figures 5G, H).Frontiers in Immunology | www.frontiersin.org 6IFNl1 With Receptor-Interacting Face
Mutations Retain Parental Kinetics
Complex and dynamic interactions between cytokine ligands
and their cognate receptors dictate the signalling output (23). To
probe further the molecular genetic basis of IFNl kinetics, we
sought to mutate and disrupt the receptor binding faces of IFNl,
hypothesising that these residues were most likely to be
responsible for IFN kinetics. IFNl4 is highly divergent when
compared with IFNl1-3 with ~30% similarity detected,A B C
FIGURE 3 | Antiviral activity against EMCV or VSV of IFNls on HepaRG and T84 cells. HepaRG (A, B) or T84 (C) cells were stimulated with different concentrations
of supernatant containing the panel of IFNls [IFNl3-HiBiT (red); IFNl4-HiBiT: WT (blue), P70S (purple), and K154E (cyan)] before being challenged with EMCV (A) or
VSV (B, C) and antiviral activity calculated, shown here as percentage of viral replication at each dilution compared to mock (EGFP conditioned media treated)
treated controls. Error bars represent the mean ± SEM from two to three biological replicates.November 2021 | Volume 12 | Article 772588





FIGURE 4 | Antiviral activity does not require continued presence of IFNls. (A) Schematic description of the experiment to show how IFNl was added and
maintained or removed by washing. T84 (B–E) and HepaRG (F–I) were stimulated with IFNls: IFNl3-HiBiT (B, F), IFNl4-HiBiT WT (C, G), P70S (D, H), and K154E
(E, I) at indicated time prior to infection with EMCV (HepaRG) or VSV (T84). VSV-luc (B–E) was assayed 8 h post-infection by quantifying the luminescence (T84).
EMCV infection (F–I) was assayed by analysis of its cytopathic effect 24 h postinfection of a series of twofold serial dilutions of supernatant. For washing experiments
(dashed lines), IFNls were removed and rinsed with PBS before being replaced with media containing virus. Error bars represent the mean ± SEM from two to four
biological replicates from one (T84) or two (HepaRG) independent protein batches. Statistical significance is shown (*p≤0.05).Frontiers in Immunology | www.frontiersin.org November 2021 | Volume 12 | Article 7725887




FIGURE 5 | Kinetics of antiviral activity of non-human primate IFNls. The percentage identity of IFNl pathway proteins (IFNl3, IFNl4, IFNlR1, and IL10R2)
between humans, chimpanzees, and/or macaques was measured using BLAST (A). A washing/incubation protocol was used (B) and HepaRG (C, D, G, H) or
rhesus macaque LL-CMK2 (E, F) cells were pretreated with IFNl4 (C, E, G) or IFNl3 (D, F, H) for the indicated times prior to infection with EMCV. Times 24
(HepaRG) or 72 (LL-CMK2) hours postinfection antiviral activity was measured by CPE assay. Antiviral activity of IFNls on HepaRG cells was measured using the
alternative washing protocol (G, H outlined in Figure 4). Results are shown as mean ± SD from four biological replicates. Data for panels (A–F) were obtained using
independent protein batches as panels (G, H).Frontiers in Immunology | www.frontiersin.org November 2021 | Volume 12 | Article 7725888
Guo et al. Interferon Lambda 4 Signallingsuggesting that there are likely to be distinct molecular
determinants of differential signalling contained within IFNl4
compared to the other human IFNls (13, 15). To begin to
identify those determinants, we constructed chimeric IFNls
between IFNl4 and human IFNl1. IFNl1 was chosen, as it is
known to have similar kinetics to IFNl3 (10) but, like IFNl4, is
N-linked glycosylated (6). Initially, comparison of differentially
conserved amino acids in IFNl4 (human and non-human
primate) with IFNl1-3 (human and macaque) identified a
divergent receptor binding interface between these groups of
IFNls suggestive of distinct receptor interactions (Figure 6A).
We focused on divergent, likely surface-exposed residues nearFrontiers in Immunology | www.frontiersin.org 9relevant helices (A, D, and F) and designed two chimeric IFNls
based on IFNl1 containing candidate IFNl4 residues from the
IFNlR1-binding helix F (F) and the IL10R2-binding helices A
and D (AD). An additional chimera with all three IFNl4 binding
helices was generated, termed ADF.
We first confirmed that IFNl1 and its chimeras were
produced and released into the supernatant using a split-
luciferase assay; this showed that chimeras incorporating
helices A and D yielded reduced production (Figure 6B). To
test their antiviral activity, HepaRG cells were pretreated for 2, 6,
or 24 h prior to EMCV infection with the WT IFNs and each of




FIGURE 6 | IFNl1 receptor-interacting interface mutants retain their kinetics. IFNl1/4 chimeras were generated based on critical differences in helices (A, D, F)
identified by alignment and comparative approaches. Specific positions in helices only were modified to those found in IFNl4 (red) (A). Relative levels of IFNls in
supernatant by HiBiT assay following transfection of expression plasmids into HEK-293T cells measured at 48 h after transfection (B). Effect of incubation time (2, 6,
or 24 h) (C) and washing (2, 6, or 24 h, washed as hashed lines) (D) of antiviral activity in HepaRG cells against EMCV was calculated as outlined previously.
Hatched line indicates limit of detection of that experiment. Error bars represent the mean ± SEM from two to four biological replicates. Data for Panel (C) was
generated using independent protein batches as Panel (D).November 2021 | Volume 12 | Article 772588
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IFNl1 with IFNl4 substitutions had reduced antiviral activity
(IFNl1 > F > AD > ADF) (Figures 6C, D). To determine if the
chimeras impacted IFN kinetics, HepaRG cells were pretreated
for 2, 6, or 24 h prior to EMCV with theWT IFNs and each of the
indicated chimeras. The IFNs were either left for the duration of
the infection or removed at the time of infection, and infection
was commenced either at time of cytokine removal or at 24 h
after initial incubation. Importantly, IFNl1 kinetics were similar
to IFNl3 in HepaRG cells, with increasing activity over time and
a delayed peak relative to IFNl4 (Figures 6C, D compared with
Figure 2F and Supplementary Figure 2). IFNl1/4 chimeras had
similar kinetic profiles as IFNl1. Results revealed that washing
reduced the antiviral potency of all IFNs and IFNl1, and all the
chimeras were more greatly affected than IFNl4. Taken with our
antiviral activity results suggested that chimera F had reduced
potency compared to IFNl1, whilst the reduced activity of AD is
likely due to reduced protein, and thus, the impact on ADF is due
to reduced amount and potency (Figure 6B). However, despite
alteration of the receptor interaction surfaces, the kinetics remain
conserved similar to IFNl1 (and IFNl3), suggesting that these
residues only modify the magnitude of the antiviral response and
are not sufficient to alter the antiviral kinetics.
Altogether, our work described here demonstrates the distinct
yet conserved antiviral kinetics of human and non-human
primate IFNl4 compared to other IFNls.DISCUSSION
Knowledge of the molecular signalling pathways stimulated by
IFN binding is essential to understand immunity to infectious
diseases and could help develop more effective interventions. The
dynamics of antiviral signalling is emerging as a physiologically
relevant and important topic, and several groups have shown
that type III IFNs have distinct slower but sustained signalling
kinetics compared to type I IFNs (10, 11, 21). Very few studies
have addressed whether different members of the type III IFN
family also have a similar kinetics for the activation of STAT1,
induction of downstream ISGs, and antiviral activity (20).
Through several lines of genetic evidence, it appears that
human IFNl4 has non-redundant functions relevant to
immunity compared to other IFNls, yet the determinants of
this unique biology are poorly understood (13, 14). Additionally,
there exist a number of naturally occurring functional variants of
IFNl4 that are known to impact potency (14, 17, 18). In this
work, we addressed whether IFNl4 WT and its variants (e.g.,
P70S and K154E) have altered antiviral kinetics, in comparison
to IFNl1 and IFNl3. By comparing IFNl4 signalling and
antiviral activity in two cell lines from two distinct organs, we
were able to identify conserved and variable features of IFNl4
and IFNl3 signalling that demonstrated distinct antiviral
kinetics, consistent with recent studies (20). Critically, we also
show that common (P70S) and rare (K154E) human variants
predominantly impact the magnitude of IFN signalling but not
the kinetics of that response, and these dynamics are largelyFrontiers in Immunology | www.frontiersin.org 10conserved in non-human primate IFNls and their cognate
cell lines.
Comparison of IFN activity across variants is notoriously
challenging given the need for input normalisation and relevant
processing. To circumvent these issues, we produced IFNl in
human cells (HEK-293T) and normalised for input IFNl using a
C-terminal “split luciferase” “HiBiT” tag system. Interestingly,
using normalised amounts of protein released into the
supernatant of transfected cells, we detected different potencies
for each IFNl, consistent with our previous work (17). In
general, IFNl3 had greater antiviral potency than WT IFNl4
in both human liver- and gut-derived cell lines. WT IFNl3
induced stronger and more prolonged STAT1 phosphorylation,
higher magnitude of ISG induction, and a stronger antiviral effect
than WT IFNl4, which induced a lower and more transient
response. The IFNl4 K154E variant displayed potency that was
more similar to IFNl3 and shows that, at least for one rare
variant, human IFNl4 has the potential to have significant
stimulatory effects. Considering the dynamics of the response,
we show clear differences between IFNl3 and IFNl4 variants
antiviral activity over time. These observations are consistent
with previous work on IFNl4 WT kinetics (20). Interestingly,
IFNl3 and IFNl4 showed differential characteristics by limiting
their contact time with target cells, suggestive of different
interactions with receptor complexes. This observation requires
more detailed biochemical and cell biology analysis, preferably
using purified proteins and receptor molecules that would allow
measurement of binding affinities, on–off rates, and their effects
on receptor trafficking, for the IFNl family. Such analysis was
beyond the scope of our study primarily due to the inherent
technical difficulties of preparing significant quantities of soluble,
correctly folded IFNl4.
The interaction between IFNls and their receptor complexes
remains poorly understood, although several crystal structures of
IFNl proteins, with the exception of IFNl4, in the presence and
absence of its heterodimeric receptor complex IFNlR1 and
IL10R2 have been solved (24, 25). There is reason to believe
that IFNl4 is likely to interact differently with its receptors based
on amino acid sequence alignments (13, 15). IFNl4 and IFNl1/
2/3 share only ~30% homology, with highest levels found in the
IFNlR1-binding “helix F.” Aside from helix F, IFNl4 differs
considerably compared to the other IFNls, including other
receptor binding helices, such as helix D that binds IL10R2. To
test the contribution of IFNl4 receptor interactors in and around
helices A, D, and F, we constructed chimeras using IFNl1 as a
reporter for antiviral activity into which we inserted predicted
receptor binding domains from IFNl4. These IFNl1/IFNl4
chimeric displayed similar kinetic profiles as IFNl1 and
IFNl3, although differences in production and potency were
noted. This suggests that the molecular determinants that
regulate binding kinetics may not lie solely in the putative
surface-exposed receptor-binding interfaces that we tested.
IFNl4 differs in structural capacity to IFNl1/3, which may not
be captured in our chimeras, and further differences are observed
in other helices that may play roles in signalling. A possible
explanation for these differences could be due to differingNovember 2021 | Volume 12 | Article 772588
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not yet been tested but could provide insight into how each
family member achieves its maximal activity. However, as most
of our assays were performed in relatively short time frames (2–6
h), it seems unlikely that IFN stability played a role in the
differences we observed and is more likely that IFNl4 interacts
and activates the receptor more rapidly, likely through binding
more strongly analogous to type I IFNs (23).
An important aspect of our work is that the differences we
detected between IFNl3 and IFNl4 in antiviral kinetics were
conserved in non-human species, through analysis of
chimpanzee and macaque IFNl4 and macaque IFNl3 in
human and macaque cell lines. This is important because
compared to other primates, humans appear to have evolved
unique IFNl4 features relevant for outcome of infectious
diseases like HCV (13, 14, 17). This finding would be
consistent with the limited genetic differences between these
species (>90% similarity). The fact that the kinetics are not
unique to humans supports the hypothesis that alterations in
IFNl4 potency has been the dominant phenotype that our recent
evolution has acted upon. It would be of interest to test further
related IFNl4, from distantly related mammals (22).
Testing IFNl kinetics in two cell lines allows us to assess
conserved and divergent activities in hepatocytes and intestinal
cells. IFNls can signal in many tissues (8), including the human
gut (21), and recent work has implicated variants in IFNl4 in the
outcome of enterovirus infection in the respiratory tract but
which can infect the gut as well (16). The role of IFNl4 in
intestinal cells up until now has been largely unexplored. Whilst
IFNl3 and IFNl4 can signal in both cell types, we show clear
differences in potency of human IFNl4 variants, consistent with
our previous work in hepatocytes. Comparing the induction of
IFNl signalling in HepaRG and T84 cells suggested that the
hepatocyte cell line was more sensitive to IFNls, yet to draw any
conclusions, primary liver and intestinal cells or organoids from
several individuals should be tested. Nevertheless, we observed
consistent kinetics differences of IFNl4 compared to IFNl3 in
both cell lines.
Our work has several implications, most importantly those
relating to the conserved differences between IFNl3 and IFNl4.
Compared to type I IFNs, IFNls have been defined partially by
their slower, sustained signalling kinetics (10, 11). IFNl4 has
several unique features, including its association with certain
diseases, transcriptional suppression, and evolution in humans,
which suggests a degree of specialisation. Unlike other IFNls,
IFNl4 appears to signal more like type I IFNs despite utilising
IFNlR1 and IL10R2. Thus, IFN kinetics may not solely lie in
receptor biology but in the interactions between cytokine and
receptor. We hypothesise that one outcome of the kinetics of
IFNl1-3 outlined here, where activity is dependent on time and
local concentration, would be a more tunable strategy, which
may have “adaptive” potential for mucosal surfaces where more
robust IFN activities may have pathogenic effects. Whether the
unique kinetics of IFNl4 would provide additional non-
redundant therapeutic benefit over other IFNls remains to
be explored.Frontiers in Immunology | www.frontiersin.org 11In conclusion, we provide further evidence of the functional
divergence of IFNl4 compared to other IFNl proteins
supporting the continued investigation into the causes and
consequences of such distinctive signalling on the human
immune system, which may be exploited for therapeutic gain.MATERIALS AND METHODS
Cell Lines
HEK-293T (human embryonic kidney) and LLC-MK2 (rhesus
macaque respiratory epithelial cell line) were cultured in high
glucose Dulbecco’s modified Eagle’s medium (DMEM) with 10%
foetal calf serum (FCS) and pen/strep. HepaRG.ISG15-EGFP
[human hepatocyte-like cell line modified to express EGFP
under the control of the endogenous ISG15 promoter (17)]
were cultured in complete William’s media with FCS (10%),
human insulin (4 µg/ml), hydrocortisone hemisuccinate (50
µM), and pen/strep (1%) (HepaRG cells). T84 (ATCC CCL-
248) colon carcinoma cells were cultured in a 50:50 mix of
DMEM:F12 with 10% FCS and 1% pen/strep on collagen-coated
cell culture dishes. All cell lines were passaged routinely
following PBS washing and trypsin-mediated detachment. Cell
lines were routinely screened forMycoplasma contamination and
discarded if signs of contamination were detected.
Viruses
Two viruses were used in this study: Ruckart strain of
encephalomyocarditis virus (EMCV) and VSV. EMCV was
produced in Vero cells following low MOI infection (MOI =
0.0001) and harvested between 1 and 2 days when extensive
cytopathic effect was observed. EMCV infectivity was quantified
by TCID50 and typically grew to titres of ~10
8/ml. VSV-luc was a
kind gift from Sean Whelan (Washington University, St. Louis)
and was produced and titrated as described in (26, 27).
Antibodies and Reagents
Commercially available primary antibodies were mouse
monoclonal antibodies recognizing b-actin (Sigma #A5441),
pSTAT1 (BD Transductions #612233), mouse anti-STAT1
antibody (3987, Abcam), or mouse anti-phospho-STAT1
antibody (29025, Abcam) and used at a 1:1,000 dilution.
Additionally, rabbit anti-beta-tubulin antibody (6046, Abcam)
was also used (1:1,000). For secondary antibodies, antimouse
(GE Healthcare #NA934V), coupled with horseradish peroxidase
(HRP), was used at a 1:5,000 dilution (T84) or horseradish
peroxidase-conjugated goat antirabbit IgG secondary antibody
(A0545, Sigma-Aldrich) at 1:2,000 dilution or horseradish
peroxidase-conjugated goat anti-mouse IgG secondary
antibody (A4416, Sigma-Aldrich) at 1:2,000 (HepaRG).
Molecular Biology
Recombinant DNA technology was utilised to generate the IFNs
for functional testing in this study, as previously described (15,
17). The mammalian expression plasmids expressing HiBiT
variants and human IFNl3, and chimpanzee (Pan troglodytes)November 2021 | Volume 12 | Article 772588
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terminal FLAG tag were described previously (17). Rhesus
macaque IFNl3-FLAG was generated synthetically (GeneArt)
with sequence corresponding to XP_001086865.3 alongside WT
IFNl1-HiBiT, or IFNl1/l4-HiBiT chimeras were constructed
synthetically (GeneArt) with sequences from helices A, D, and F
as shown (Figure 5) and cloned into expression vector pC1 and
sequenced confirmed by Sanger sequencing. Correct plasmids
were purified by midiprep or maxiprep and quality and quantity
determined by NanoDrop prior to transfection. An EGFP
expression plasmid prepared in identical conditions was used
as a negative control throughout.
IFN Production
IFNls were produced using the protocol described previously,
which is capable of generating functional IFNls (17). Briefly,
IFN expression plasmids were transfected into sub-confluent
HEK-293T cell monolayers, which are hyporesponsive to IFNl
signalling due to very low expression of IFNlR1 (15).
Lipofectamine 2000 was used to transfect IFNl plasmids per
manufacturer’s instructions. IFNls were routinely generated in
six-well plates or 10 cm dishes, and 2 and 14 µg of plasmids were
used, respectively. Lipofectamine 2000 (2 µl) was used per
microgram of plasmid. Plasmids were transfected into cells in
Optimem for 16–18 hours, before changing media to growth
media (10% FCS) until 2 days posttransfection was reached. The
conditioned media were harvested, clarified by centrifugation,
aliquoted, and immediately frozen at −80 in. Relative levels of
IFNls were estimated using the extracellular HiBiT split
luciferase assay by virtue of their C-terminal HiBiT tag by
incubating IFN preparations with assay reagents and measured
by manufacturer’s instructions (Nano-Glo HiBiT Extracellular
Detection system, Promega) using a luminometer.
Interferon Treatments
For quantitative real-time PCR (qRT-PCR) or immunoblotting
experiments, IFN stimulation was achieved by incubating cell
monolayers with IFNl-containing conditioned media at a
defined concentration to have equivalent HiBiT signal for each
sample. Cells treated with IFNs were incubated for the indicated
period of time before either being processed. A previous titration
analysis indicated that a ~1:2–1:4 dilution of IFNl4-WT is
enough to give a robust induction of ISGs for all variants (17)
and antiviral response whilst limiting the amount of conditioned
media added to cells (<50% of total volume). Therefore, WT
IFNl4 was used at the standard, and the levels of other IFNs were
normalised to this by virtue of the HiBiT tag. Based on HiBiT
assay measurements, the relative ratios of supernatant were
IFNl4(WT):P70S:L79F:K154E:IFNl3, ~1:2:2:0.2:0.01. For the
analysis of pSTAT1 levels by immunoblotting, 100,000 cells
were seeded in 500 µl of growth media, into sterile rat-tail-
collagen-coated (T84) or untreated (HepaRG) 24-well plates. To
analyse ISG expression levels by qRT-PCR, 50,000 T84 cells were
seeded in 500 µl DMEM/F12 into sterile rat-tail-collagen-coated
48-well plates, or 1,000,000 HepaRG cells were seeded into 2 ml
of growth media into 6-well plates. Cells were treated either with
HEK293T cell supernatants containing either IFNl3 or differentFrontiers in Immunology | www.frontiersin.org 12IFNl4 variants [l4 wild type (WT), K154E, P70S] or GFP-
conditioned medium (Mock). Prior to treatment, media were
removed; cells were rinsed once in PBS and then treated with
each IFN diluted in their corresponding growth media to achieve
an equal concentration (as determined by HiBiT) and added to
the cells in 500−1,000 µl/well. Cells were then incubated at 37°C
and 5% CO2 until harvest. Cells were harvested at 15 min, 30
min, 1 h, 2 h, 4 h, 24 h, and 48 h posttreatment for the analysis of
pSTAT1 protein levels by immunoblotting, whereas total RNA
was isolated from T84 cells at 2, 4, 8, 12, and 24 h posttreatment
for the analysis of ISG expression levels by qRT-PCR. To control
for batch-to-batch variability in protein production, at least two
independent protein preps were used.
Viral Infections
For the EMCV antiviral assays, 5,000 cells were seeded per well in
a 96-well plate 24 h prior to treatment. At the day of treatment,
IFNs were added in twofold serial dilutions to the cells 24 h prior
to infection. Following IFN treatment, EMCV (MOI = 0.3) was
added to the cells, and infection was scored by CPE 24hpi
visually or by crystal violet staining. EMCV is highly
cytopathic in certain cell lines and very sensitive to IFN. The
reciprocal of the dilution giving ~50% protection was used as a
semiquantitative measure of IFNl-conditioned media activity.
For VSV infection, T84 or HepaRG cells were seeded in a
white bottom 96-well plate. Cells were pretreated prior to
infection as indicated time points and concentrations of IFN-
l3 and IFN-l4, and its variants K154E and P70S. VSV-luc
(MOI = 1) was added to the wells, and the infection was
allowed to proceed for 8 h. At the end and the infection,
media was removed, cells were washed 1× with PBS and lysed
with cell lysis buffer (Promega) at room temperature (RT) for 20
min. The same volume of Steady Glo (Promega) was added to the
cells and incubated for 15 min. Luminescence was read using
Tecan Infinite M200 Pro.
Immunoblotting
At the time of harvest, cells were rinsed once with PBS and then
lysed with 1× radioimmunoprecipitation assay (RIPA) buffer
[150 mM sodium chloride, 1.0% Triton X-100, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulphate (SDS), 50 mM Tris
at pH 8.0 supplemented with phosphatase and protease
inhibitors (Sigma-Aldrich or Thermo Fisher) for 5–10 min at
RT (T84) or ice (HepaRG)]. Cell lysates were collected, and
roughly equal amounts of protein were then separated by SDS-
PAGE in a 10% (HepaRG) or 12% (T84) polyacrylamide gel,
following boiling and reducing. Lysates were then blotted onto a
nitrocellulose membrane (T84) or PVDF (HepaRG) by wet
blotting. Membranes were blocked with blocking buffer [5%
BSA in TBS containing 0.1% Tween-20 (TBS-T)] for 1 h at RT
whilst shaking. Primary antibodies (1:1,000 dilution) were
diluted in blocking buffer and incubated overnight shaking at
4°C. The membranes were washed four times in TBS-T for 10
min at RT. Then, secondary antibodies were diluted in blocking
buffer and incubated for 1 h shaking at RT. Membranes were
again washed four times in TBS-T for 10 min at RT. HRP
detection reagent (GE Healthcare) was mixed 1:1 and incubatedNovember 2021 | Volume 12 | Article 772588
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crescendo western HRP substrate, WBLUR0100, Merck).
Membranes were then exposed to film and developed or
visualised by chemiluminescence using the G:BOX Chemi gel
doc Imaging System Instrument (Syngene). The detection of b-
actin (T84) or b-tubulin (HepaRG) was used as loading controls.
For quantitative analysis, pSTAT1 intensities of each
immunoblot were quantified for each timepoint using ImageJ
or Image Studio Lite Version 5.2. For quantification with ImageJ,
the background value (Mock) was manually subtracted from the
calculated values. pSTAT1 levels were then determined relative
to control.
RT-qPCR
The total RNA was purified from lysed cells using the Nucleo
Spin® RNA extraction kit (T84) by Marchery-Nagel (Catalog
number 740955.50) according to the manufacturer’s instructions
or (HepaRG) RNeasy Mini Kit (74106, Qiagen). RNA
concentration was measured using the NanoDrop Lite
spectrophotometer (Thermo Scientific). For T84 cells, 250 ng
of total RNA was reverse transcribed into cDNA using the
iScript™ cDNA Synthesis kit (BioRad Laboratories, Catalog
number 1708891). The reaction contained a mixture of 1 ml
Reverse Transcriptase, 4 ml Reaction Mix, and 15 ml of RNA
template in nuclease-free water. The newly synthesised cDNA
was diluted 1:2 in RNase/DNase free water. The following qRT-
PCR was performed using a Bio-Rad CFX96 Real-Time PCR
Detection System. Per reaction 7.5 µl of SsoAdvanced Universal
SYBR Green Supermix, 2 µl of 1:2 diluted cDNA, 1.7 µl of
nuclease free water, and 1.9 µl of either forward or reverse
primers (2 µM) for the amplification of IFIT1 (fw: 5′-AAAAG
CCCACATTTGAGGTG-3′; rev: 5′-GAAATTCCTGAAA
CCGACCA-3′), ISG15 (fw: 5′-CCTCTGAGCATCCTGGT-3′;
rev: 5′-AGGCCGTACTCCCCCAG-3′), Viperin (fw: 5′-
GAGAGCCATTTCTTCAAGACC-3′ and rev: 5′-CTATAATC
C C TACACCACC TC C - 3 ′ ) , a n d M x 1 ( f w : 5 ′ -
GGTCTATACCACACGCACAGA-3′; rev: 5′- ACTGGTT
TCCTTTGCCTCGT-3′) were used. Data analysis was
performed using the Bio-Rad CFX Manager 3.0. The
expression of the targeted genes was then normalised to the
housekeep ing gene HPRT1 ( fw : 5 ′ -CCTGGCGTC
GTGATTAGTGAT-3′; rev: 5′-AGACGTTCAGTCCTGT
CCATAA-3′). For HepaRG cells, 1 mg of total RNA was
reverse transcribed into cDNA using the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, UK). The
reaction contained a mixture of 1 ml Reverse Transcriptase, 9
ml Reaction Mix, and 10 ml of RNA template in nuclease-free
water. The newly synthesised cDNA was diluted 1:25 in RNase/
DNase free water. The following qRT-PCR was performed using
a Real-Time Ready PCR Kit (Roche) and TaqMan primer–
primer–probe mixes. Each reaction mixture consisted of 10 ml
of 2× LightCycler 480 Probes Master, 1 ml of 20× Real-Time
Ready Assay with 4 ml PCR-grade H2O (total volume, 15 ml).
Template DNA, defrosted on ice, was first diluted 1:25 (v/v) with
PCR-grade H2O and then 5 ml diluted template added per
reaction tube to the probes MasterMix to give a final volume
of 20 ml. TaqMan assays (Catalogue number 4331182) for IFIT1Frontiers in Immunology | www.frontiersin.org 13(Assay ID: Hs03027069_s1), ISG15 (Assay ID: Hs01921425_s1),
MX1 (Assay ID: Hs00895608_m1), and RSAD2/VIPERIN (Assay
ID: Hs00369813_m1) were used. The expression of the targeted
genes was then normalised to the housekeeping gene GAPDH
(Assay ID: Hs02786624_g1). Cells treated with conditioned
media from EGFP-plasmid transfected HEK-293T cells were
used as a mock control, and all values were normalised against
this value at each time as “fold change to EGFP.”DATA AVAILABILITY STATEMENT
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Supplementary Figure 1 | pSTAT1 quantification over time for IFNls on liver and
gut cells. Quantification of pSTAT1 from images in Figure 1 compared to house-
keeping control and background levels was carried out by densitometry analysis forNovember 2021 | Volume 12 | Article 772588
Guo et al. Interferon Lambda 4 SignallingHepaRG (A) and T84 (B) cells (IFNl3-HiBiT [red], IFNl4-HiBiT: WT [blue], P70S
[purple], and K154E [cyan].
Supplementary Figure 2 | Effect of IFN incubation time on kinetics of human
IFNl variants. HepaRG cells were stimulated with IFNls: IFNl3-HiBiT (red), IFNl4-Frontiers in Immunology | www.frontiersin.org 14HiBiT variants: WT (blue), P70S (purple), and K154E (cyan) at indicated times (2, 6 or
24h) before supernatant was removed and rinsed with PBS before being replaced
with fresh media not containing virus (A). Stimulated cells were incubated until 24h
after IFNl incubation prior to infection with EMCV and antiviral activity was read
24hpi (B). Error bars represent the mean ± SEM from 2 biological replicates.REFERENCES
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14. Terczyńska-Dyla E, Bibert S, Duong FHT, Krol I, Jørgensen S, Collinet E, et al.
Reduced Ifnl4 Activity Is Associated With Improved HCV Clearance and
Reduced Expression of Interferon-Stimulated Genes. Nat Commun (2014)
5:5699. doi: 10.1038/ncomms6699
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